Treating beyond trial eligibility: a pragmatic, prospective phase II study of first-line immunotherapy regimens in advanced non–small cell lung cancer patients with borderline performance status
Background Approximately 20-40% of patients with metastatic non-small cell lung cancer (mNSCLC) present with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, yet are systematically excluded from pivotal immunotherapy trials. Current guidelines recommend similar first-line regimens for PS0–1 and PS2 patients based on extrapolated data, creating clinical uncertainty. Methods This single-center, pragmatic pilot phase II study compares outcomes of standard first-line immunotherapy-based regimens between PS2 and PS0–1 patients with mNSCLC. Eligible patients receive NCCN-preferred regimens selected by treating providers per standard care. The primary outcome is 3-month progression-free survival (PFS), defined as the proportion without disease progression after four treatment cycles. Secondary outcomes include treatment-related adverse events and patient-reported quality of life changes. The study employs a non-inferiority design (margin –0.20 absolute difference in 3-month PFS proportion, α 0.05, 83% power) to assess whether PS2 patients achieve comparable early disease control to PS0–1 patients. Anticipated results We hypothesize that selected PS2 patients will demonstrate non-inferior 3-month PFS compared to PS0–1 patients when treated with standard immunotherapy-based regimens, with acceptable toxicity and quality of life outcomes. Conclusion This pragmatic trial addresses a critical evidence gap by prospectively evaluating whether performance status alone should preclude use of standard immunotherapy-based regimens in mNSCLC, providing data to inform shared decision-making for this underrepresented population. Clinical trial registration https://clinicaltrials.gov/study/NCT04253964 , identifier NCT04253964.
Authors
- Thomas William Lycan (ORCID: https://orcid.org/0000-0001-9475-1558)
- John C. Hunting (ORCID: https://orcid.org/0000-0002-4066-4763)
- Sarah N. Price (ORCID: https://orcid.org/0000-0002-1622-1700)
- William J. Petty
- David Soto-Pantoja
- Beverly J. Levine
- Stefan Grant
- Yaffa Ali
- Haley W. Mabry
Institutions
- Tulane University (US)
- Wake Forest University Health Sciences (US)
- Wake Forest University (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fonc.2026.1929978
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Comprehensive Cancer Center at Wake Forest Baptist Medical Center